The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
Treatment of patients with metastatic carcinoma of the colon or rectum E3200
Gastrointestinal Cancers
Colorectal Cancer
-
E3200
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Panitumumab
-
Best supportive care
Treatment of patients with wild-type RAS mCRC after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing ChT regimens Study 20020408
Gastrointestinal Cancers
Colorectal Cancer
RAS-WT
Study 20020408
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Oxaliplatine
FOLFIRI + bevacizumab
FOLFIRI + bevacizumab
Treatment of patients with metastatic carcinoma of the colon or rectum TRIBE
Gastrointestinal Cancers
Colon and Rectal Cancer
-
TRIBE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Regorafenib
-
Placebo
Treatment of patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based ChT, an anti-VEGF therapy and an anti-EGFR therapy CORRECT
Gastrointestinal Cancers
Colorectal Cancer
-
CORRECT
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Aflibercept
FOLFIRI
FOLFIRI + placebo
Metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimenVELOUR
Gastrointestinal Cancers
Colorectal Cancer
-
VELOUR
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Bevacizumab
Chemotherapy
Chemotherapy
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based ChT for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen ML18147
Gastrointestinal Cancers
Colon and Rectal Cancer
-
ML18147
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Epirubicin, 5-FU, Cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaMAGIC
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
MAGIC
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU, Cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaFRE-FNCLCC-94012
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
FRE-FNCLCC-94012
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
Ramucirumab
Paclitaxel
Paclitaxel + placebo
Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine ChTRAINBOW
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
RAINBOW
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Ramucirumab
-
Placebo
Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine ChT, when treatment in combination with paclitaxel is not appropriateREGARD
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
REGARD
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
FOLFIRINOX
-
Gemcitabine
First-line metastatic pancreatic cancer in patients with good performance statusPRODIGE 4/ACCORD 11
Gastrointestinal Cancers
Pancreatic cancer
-
PRODIGE 4/ACCORD 11
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nab-paclitaxel
Gemcitabine
Gemcitabine
Nab-paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreasMPACT
Gastrointestinal Cancers
Pancreatic cancer
-
MPACT
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Erlotinib
Gemcitabine
Gemcitabine + placebo
Erlotinib in combination with gemcitabine for the treatment of patients with metastatic pancreatic cancerPA.3
Gastrointestinal Cancers
Pancreatic cancer
-
PA.3
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Bevacizumab
Combination chemotherapy
Combination chemotherapy
In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervixGOG 240
Gynaecological Malignancies
Cervical Cancer
-
GOG 240
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Bevacizumab
Chemotherapy
Paclitaxel or topotecan or liposomal doxorubicin
In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agentsAURELIA
Gynaecological Malignancies
Ovarian Cancer
-
AURELIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancerICON7
Gynaecological Malignancies
Ovarian Cancer
-
ICON7
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
1
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced (FIGO stage IIIB, IIIC, IV) epithelial ovarian, fallopian tube, or primary peritoneal cancerICON7
Gynaecological Malignancies
Ovarian Cancer
High risk
ICON7
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Bevacizumab
Gemcitabine + carboplatin
Gemcitabine + carboplatin
In combination with carboplatin and gemcitabine for treatment of adult patients with first recurrence platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agentsOCEANS
Gynaecological Malignancies
Ovarian Cancer
-
OCEANS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Bevacizumab
Carboplatin + paclitaxel
Paclitaxel and carboplatin (6 cycles)
Incompletely resected stage III and stage IV ovarian cancerGOG-0218
Gynaecological Malignancies
Ovarian Cancer
-
GOG-0218
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
gBRCA
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
non-gBRCA HRD +ve
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
non-gBRCA
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
Platinum sensitive
OVA-301
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
-
OVA-301
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Olaparib
-
Placebo
Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (Phase II)Study 19
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA mutation
Study 19
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Cediranib
Chemotherapy
Platinum-based chemotherapy + placebo and placebo maintenance
Platinum-sensitive relapsed ovarian cancerICON 6
Gynaecological Malignancies
Ovarian Cancer
-
ICON 6
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
1
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.